These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 24336297

  • 1. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results.
    Kriechbaum K, Prager S, Mylonas G, Scholda C, Rainer G, Funk M, Kundi M, Schmidt-Erfurth U, Diabetic Retinopathy Research Group.
    Eye (Lond); 2014 Jan; 28(1):9-15; quiz 16. PubMed ID: 24336297
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S, Rush R, Natarajan S, Gillies M.
    Clin Exp Ophthalmol; 2011 Jan; 39(7):673-81. PubMed ID: 22452685
    [Abstract] [Full Text] [Related]

  • 3. Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year.
    Mylonas G, Schranz M, Scholda C, Karst S, Reiter G, Baumann L, Schmidt-Erfurth U, Kriechbaum K.
    Curr Eye Res; 2020 Sep; 45(9):1107-1113. PubMed ID: 31961224
    [Abstract] [Full Text] [Related]

  • 4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X, Li J, Hu X, Yu S, Pan J, Tang S.
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.
    Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR.
    Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):483-9. PubMed ID: 17917738
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW, Cardillo JA, Messias A, Siqueira RC, Scott IU, Jorge R.
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Refractive changes after pharmacologic resolution of diabetic macular edema.
    Deák GG, Lammer J, Prager S, Mylonas G, Bolz M, Schmidt-Erfurth U, Diabetic Retinopathy Research Group Vienna.
    Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results.
    Lim LL, Morrison JL, Constantinou M, Rogers S, Sandhu SS, Wickremasinghe SS, Kawasaki R, Al-Qureshi S.
    Clin Exp Ophthalmol; 2016 May; 44(4):233-42. PubMed ID: 26871700
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.